Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data

414 patients with chronic kidney disease (CKD), mean age 63 years, 72% male. Inclusion criteria: ≥18 years of age with an estimated glomerular filtration rate (eGFR) of ≥45 but <60 mL/min/1.73 m2 and urine albumin:creatinine ratio (uACR) >20 mg/mmol or eGFR ≥20 but <45 mL/min/1.73 m2 (regardless of uACR).

Sacubitril/valsartan 97/103 mg two times daily for 12 months

Irbesartan 300 mg one time daily for 12 months

Measured GFR after 12 months of therapysurrogate